Qing Wen, Maohua Huang, Jingwen Xie, Runyu Liu, Qun Miao, Jinjun Huang, Junqiu Zhang, Wenyu Lyu, Ming Qi, Chunyi Wu, Qi Qi, Zhijing Zhang, Rong Deng, Chenran Wang, Zhe-Sheng Chen, Dongmei Zhang, Wencai Ye, Minfeng Chen
AIMS: Vessel co-option is responsible for tumor resistance to antiangiogenic therapies (AATs) in patients with colorectal cancer liver metastasis (CRCLM). However, the mechanisms underlying vessel co-option remain largely unknown. Herein, we investigated the roles of a novel lncRNA SYTL5-OT4 and Alanine-Serine-Cysteine Transporter 2 (ASCT2) in vessel co-option-mediated AAT resistance. METHODS: SYTL5-OT4 was identified by RNA-sequencing and verified by RT-qPCR and RNA fluorescence in situ hybridization assays...
July 2023: Drug Resistance Updates: Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy